Surviving a brain disorder is only half the battle. For millions of patients, long-lasting cognitive impairment reshapes daily life. This persistent damage is driven by neurodegeneration, a shared hallmark across major disorders of the central nervous system, including global cerebral ischemia, spinal cord ischemia, stroke, and Alzheimer’s disease.

Despite tremendous effort, there are no approved therapies that directly prevent neurodegeneration. The ideal therapy would go beyond prevention of cell death to also restore normal function. To that end, Neurexis is advancing tatCN19o, a first-in-class, optimized peptide therapeutic designed to target a key signaling molecule downstream of glutamate excitotoxicity. With applicability across multiple high-value indications, Neurexis is pursuing significant, untreated markets with compelling unmet medical need.